Avène Retrinal Multi-Corrective Cream: which formula owns the evidence?

The current product record identifies the Multi-Corrective cream as a 1 fl oz item at $68 and says it has an improved formula. Its SKU is P0008259. These details distinguish the review’s subject from the retired preparation and help a reader recognize which official record is being discussed.

The retired page identifies a different SKU, P0008150, and directs readers toward the new formulation. That evidence supports a version distinction, not an assumption that every older bottle or saved review describes the current cream. The INKEY Starter serum review offers another product discussion where exact identity is useful before trying to interpret ingredient or result headlines.

Avène’s current full ingredient list names retinal, niacinamide, glycerin and squalane, among other ingredients. The product advertises 0.1% retinaldehyde. These are details about the current manufacturer-described formulation, not a concentration assay or an inspected bottle.

Retinal naming should remain distinct from retinol, and neither name identifies prescribed tretinoin. The AAD’s retinoid explanation distinguishes the larger family and the prescription-versus-retail context. The reviewed declaration also does not assess anyone’s sensitivity or existing treatment. It is useful preparation-specific information, but cannot by itself establish a clinical result or transfer the approval of a different medicine to this cream.

The current summary reports improvements in texture, firmness and smoothness for 89%, 92% and 87%, respectively. Its footnote identifies 44 women aged 45–65 over 57 days. Those details give the summary a defined group and period. They do not identify the full assessment method or provide the underlying report.

The wording says improvement was seen, but does not establish whether each endpoint was self-rated, observer-graded or measured by an instrument. We leave that method unresolved. Our fine-lines and deeper-wrinkles guide helps identify another limit: texture, firmness and smoothness are specific appearance concerns. They should not be silently expanded into removal of every wrinkle or a predictable result for a different participant group.

The manufacturer’s footnotes connect three-times wording with a 1994 human-skin retinaldehyde paper and ten-times wording with a 1990 paper concerning retinol and retinal metabolism in cultured human keratinocytes. We read the citations on the product page, not the full underlying papers.

Their described subjects do not establish a clinical comparison of the finished current cream against another retail product. A cultured-cell reference is especially different from an appearance endpoint reported by women using a cream. The Paula’s Choice treatment review provides another separate evidence discussion. The purpose of reading both is to ask what each claim rests on, rather than combine derivative names and multipliers into a clinical strength ranking.

The retired official record supplies its own full ingredient list and study footnotes. One describes crow’s-feet and the area around the eyes in 23 women after eight weeks; another describes analog-scale scoring by 23 subjects. Those are more specific method and body-site details than a generic anti-aging label.

They still belong to the prior preparation. The old reduction and texture figures cannot be attached to the improved formula because its name is similar or because both lists contain retinal. The photograph evidence guide explains why preparation, observation conditions and the actual assessed feature matter. Even genuine findings can be misread when the formula or the subject of the result changes.

The current page text supports the named quantity and $68 offer. The retired page displays $79 and describes discontinuation. These are different product records; the older amount should not become today’s price for the improved cream or a suggestion that the formulations were clinically compared by cost.

Direct page retrieval was blocked, so the official text here comes through indexed fallback records with an unknown upstream clock. We did not complete a purchase or verify present stock. The fine-line options comparison provides broader context for keeping an advertised preparation, its commercial terms and the evidence for its results as three connected but separate questions.

For the current cream, the most useful unresolved details are the full study method and whether its reported appearance endpoints match the reader’s concern. A new formula cannot inherit old percentages, and an ingredient reference cannot become a head-to-head result for the finished product. The current manufacturer record should remain the starting point for that exact preparation.

The AAD emphasizes professional assessment when considering a retinoid and describes skin-specific comfort concerns. It does not endorse this cream or determine a reader’s suitability. The review therefore offers no application instructions, individual tolerance assurance or prescription substitution. Its contribution is to separate the evidence that exists from the conclusions a familiar name or a striking multiplier might otherwise invite.